- CEO
- Reiko Yasue
- Full Time Employees
- 571
- Sector
- Technology
- Industry
- Software - Application
- Address
- FUJISOFT Building Tokyo Japan 101-0022
- IPO Date
- Nov 30, 2022
- Business
- Cybernet Systems Co., Ltd. (Ticker: CBSZF) provides computer-aided engineering (CAE) technologies and IT solutions worldwide, with operations through CAE Solutions and IT Solutions segments; the former develops and sells CAE software including mechanical, control, optical, measurement, and CAE platforms such as Ansys software, Flownex simulation environment, CETOL 6σ tolerance analysis, and Neural Concept Shape AI tool, while also offering engineering services like contract analysis, consulting, technical support, and education; the latter delivers cybersecurity solutions encompassing endpoint security, cloud security, and IT asset management, alongside MBSE/MBD tools for complex development processes, IoT/XR platforms including ThingWorx and Vuforia for digital twins and AR/VR, big data visualization, and medical AI diagnostic support such as EndoBRAIN-EYE series. Founded April 17, 1985 and headquartered in Tokyo, Japan, the company serves manufacturing R&D, universities, and research institutes primarily in Japan, with subsidiaries and partners including Cybernet Systems Taiwan Co., Ltd., Cybernet Systems (Shanghai) Co., Ltd., Cybernet Systems Malaysia Sdn. Bhd., Sigmetrix L.L.C., Maplesoft, and Noesis Solutions NV across Asia, Europe, and North America; it caters to industries spanning automotive, electronics, healthcare, energy, and agriculture. Recent developments include delisting from the Tokyo Stock Exchange in February 2024 following a takeover bid by parent Fujisoft Incorporated, Sigmetrix launching VariSight v1.0 enterprise variation management software and CETOL v12 3D tolerance analysis in early 2025, Cybernet Malaysia earning the 2024 Ansys ASEAN & ANZ Channel Partner of the Year – Marketing Excellence award, Multiscale.Sim integrating with Moldex3D and joining the Ansys Technology Partner program in 2024, and EndoBRAIN-EYE securing add-on public health insurance reimbursement in Japan.